Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
In the latest session, BioNTech SE ADR (NASDAQ: BNTX) closed at $108.80 down -4.56% from its previous closing price of $114.00. In other words, the price has decreased by -$4.56 from its previous closing price. On the day, 0.81 million shares were traded.
Ratios:
For a deeper understanding of BioNTech SE ADR’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.40 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.64. For the most recent quarter (mrq), Quick Ratio is recorded 7.21 and its Current Ratio is at 7.33. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Truist on January 10, 2025, initiated with a Buy rating and assigned the stock a target price of $172.
On December 11, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $170.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 27 ’25 when Richardson Ryan bought 26,500 shares for $114.00 per share.
Medine GmbH bought 1,000,000 shares of BNTX for $119,580,000 on Feb 20 ’25. On Feb 20 ’25, another insider, Poetting Sierk, who serves as the Officer of the company, bought 120,000 shares for $119.58 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 7.90 while its Price-to-Book (P/B) ratio in mrq is 1.22.
Stock Price History:
Over the past 52 weeks, BNTX has reached a high of $131.49, while it has fallen to a 52-week low of $76.53. The 50-Day Moving Average of the stock is -7.04%, while the 200-Day Moving Average is calculated to be 4.41%.
Shares Statistics:
A total of 239.74M shares are outstanding, with a floating share count of 235.99M. Insiders hold about 1.57% of the company’s shares, while institutions hold 20.84% stake in the company.
Earnings Estimates
Its stock is currently analyzed by 14.0 different market analysts. The consensus estimate for the next quarter is -$2.07, with high estimates of -$1.23 and low estimates of -$2.99.
Analysts are recommending an EPS of between -$1.29 and -$5.76 for the fiscal current year, implying an average EPS of -$3.29. EPS for the following year is -$3.42, with 20.0 analysts recommending between -$0.06 and -$7.92.
Revenue Estimates
A total of 13 analysts believe the company’s revenue will be $1.15B this quarter.It ranges from a high estimate of $1.75B to a low estimate of $866.38M. As of the current estimate, BioNTech SE ADR’s year-ago sales were $1.48BFor the next quarter, 13 analysts are estimating revenue of $219.49M. There is a high estimate of $382.5M for the next quarter, whereas the lowest estimate is $145M.
A total of 20 analysts have provided revenue estimates for BNTX’s current fiscal year. The highest revenue estimate was $2.86B, while the lowest revenue estimate was $2.4B, resulting in an average revenue estimate of $2.65B. In the same quarter a year ago, actual revenue was $3.82BBased on 20 analysts’ estimates, the company’s revenue will be $2.54B in the next fiscal year. The high estimate is $3.37B and the low estimate is $1.81B.
